Clovis Oncology (CLVS.Q) Aperçu de l'action
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 2/6 |
| Croissance future | 0/6 |
| Performances passées | 0/6 |
| Santé financière | 0/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
CLVS.Q Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Clovis Oncology, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$0.015 |
| Plus haut sur 52 semaines | US$2.87 |
| Plus bas sur 52 semaines | US$0.01 |
| Bêta | 0.66 |
| Variation sur 1 mois | -40.00% |
| Variation sur 3 mois | -28.57% |
| Variation sur 1 an | -99.39% |
| Variation sur 3 ans | -99.77% |
| Variation sur 5 ans | -99.97% |
| Évolution depuis l'introduction en bourse | -99.88% |
Nouvelles et mises à jour récentes
Seeking Alpha • Sep 21
Clovis Oncology rises on clinical supply agreement with Isotopia
Clovis Oncology (NASDAQ:CLVS) said on Wednesday it had signed a clinical supply agreement that would provide it with Isotopia’s lutetium-177 n.c.a. for use in the development of FAP-2286, fibroblast activation protein, that targets therapeutic candidate. (CLVS) has risen 4.5% before the bell. FAP-2286 is currently being developed in the Phase 1/2 study to treat patients with advanced solid tumors. The agreement covers an initial period of two years. "Over the past four years, Isotopia has strengthened its supply chain to support the growing global demand and need for higher supply security," said Keren Moshkoviz, Deputy CEO and BD at Isotopia. FAP is highly expressed by cancer-associated fibroblasts (CAFs) which are found in the majority of cancer types, but with limited expression in healthy fibroblasts, potentially making it a suitable target across a wide range of tumors.Seeking Alpha • Sep 12
Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial
Clovis Oncology (NASDAQ:CLVS) said Rubraca as initial maintenance therapy improved progression-free survival (PFS), compared to placebo across disease risk subgroups in patients with ovarian cancer. The company presented data from a subgroup analysis of a monotherapy comparison in the phase 3 trial called ATHENA at the European Society of Medical Oncology (ESMO) Congress 2022 in Paris. ATHENA-MONO enrolled 538 women with high-grade ovarian, fallopian tube or primary peritoneal cancer. Patients who received Rubraca as maintenance therapy showed PFS (length of time during/after therapy a patient lives with the disease without it getting worse) benefit regardless of surgical outcome, whether there was complete resection during cytoreductive surgery or not, the company said in a Sept. 11 press release. In addition, patients treated with Rubraca as maintenance therapy showed benefit among all subgroups when evaluated against response per RECIST v1.1 at any time during first-line chemotherapy. Clovis noted that in other subgroups based on baseline clinical characteristics, including FIGO stage, timing of surgery, and CA-125 levels, also showed that patients treated with Rubraca experienced a PFS benefit compared to those treated with placebo. CLVS +14.78% to $1.32 premarket Sept. 12Seeking Alpha • Aug 11
Clovis Oncology: Needs Some Encouraging Data Quickly
Funding difficulties have definitely been priced into Clovis' share price. Clovis, though, has some interesting readouts due this year and in early 2023. If data is encouraging and new funding is announced, CLVS stock could rally sharply from present levels. Intro If we look at a long-term chart of Clovis Oncology, Inc. (CLVS) (Antin Cancer Biotech Company), we see that shares topped out in 2017 and have been making sustained lower lows ever since. Suffice it to say, a lot of shareholders have been burned by this play, and if the present bearish trend continues, shares could easily test the stock's year-to-date lows of well under $1 a share. If indeed though shares swoop down to their 2022 lows in the not too distant future, the risk/reward play would be heavily skewed to the upside because of what the company still has in its locker in our opinion. Clovis Technical Chart (Stockcharts.com) Clovis Needs Capital Suffice it to say, it then would boil down to how much the company's assets are worth to a partner if indeed a third party is to enter the scene here, which now looks highly likely. Management announced on its recent quarterly earnings call that raising capital through public or private equity means is not an option at present due to the recent unsuccessful stock split. So, Clovis' current options with respect to facilitating funding seem to be to either increase the number of shares or enter into some type of licensing agreement. The reason being is that when forward-looking revenue projections and the company´s current cash-burn rate are taken into account, operations will eventually come to a grinding halt in early 2023 if no new funding is found. Rubraca Sales Are Not Growing Unfortunately, Rubraca has not performed up to expectations. This means Clovis' pipeline has literally run out of time. Rubraca sales came in at $32.1 million in the company's fiscal second quarter, which was a 6% sequential decline as well as a 13% decrease compared to the same period of 12 months prior. Covid-19 has been a clear headwind here due to fewer numbers of people going through the system. This has led to a fall-off in second-line maintenance treatment. Furthermore, recent insider selling demonstrates management's outlook on how Rubraca is expected to fare going forward, which obviously has been factored in as to when the firm will run out of money. Pipeline However, with respect to the pipeline, management was quick to point to the ongoing FAP-2286 (Lead candidate in Radionuclide therapy) LuMiere trial with respect to its recent encouraging results. When we take into account the tumor space, which is a significant area of high unmet need, along with recent evidence regarding Fap-2286's sound safety and clinical implications, this will be a trial that will be watched very closely going forward by all cohorts in this space. Then, on the Rubraca side, the ongoing TRITON3 & ATHENA studies offer the opportunity to bring to the market earlier therapy solutions for prostate and ovarian cancer patients. Regarding ovarian cancer, Clovis has plenty of indications in late stages in ATHENA-MONO & ATHENA-COMBO, where we should have updated information in this space in the latter stages of this fiscal year as well as early next year. Remember, the goal here is to widen the net so to speak with respect to patients undergoing therapy in this space. The same goes for specific prostate cancer patients in the TRITON3 trial where we should have an update over the next few months or so. Worrying Financials The question then becomes how much is this pipeline worth, notwithstanding Rubraca's U.S. and international product revenues. Remember, Clovis has well over $600 million of long-term debt on its balance sheet and continues to report negative shareholder equity. Suffice it to say, its bargaining position is not healthy, as the company will most likely have to give up more than it wishes to attract the interests of a funded third party.Recent updates
Rendement pour les actionnaires
| CLVS.Q | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | 18.1% | -1.6% | -0.8% |
| 1Y | -99.4% | 34.4% | 27.1% |
Rendement vs Industrie: CLVS.Q a sous-performé le secteur US Biotechs qui a rapporté 34.4 % au cours de l'année écoulée.
Rendement vs marché: CLVS.Q a sous-performé le marché US qui a rapporté 27.1 % au cours de l'année écoulée.
Volatilité des prix
| CLVS.Q volatility | |
|---|---|
| CLVS.Q Average Weekly Movement | 61.3% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: Le cours de l'action de CLVS.Q a été volatil au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de CLVS.Q est passée de 39% à 61% au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2009 | 413 | Patrick Mahaffy | www.clovisoncology.com |
Clovis Oncology, Inc. Résumé des fondamentaux
| CLVS.Q statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$2.18m |
| Bénéfices(TTM) | -US$251.91m |
| Recettes(TTM) | US$133.02m |
0.0x
Ratio P/S0.0x
Ratio P/ELe site CLVS.Q est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| CLVS.Q compte de résultat (TTM) | |
|---|---|
| Recettes | US$133.02m |
| Coût des recettes | US$31.59m |
| Marge brute | US$101.43m |
| Autres dépenses | US$353.33m |
| Les revenus | -US$251.91m |
Derniers bénéfices déclarés
Sep 30, 2022
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -1.73 |
| Marge brute | 76.25% |
| Marge bénéficiaire nette | -189.37% |
| Ratio dettes/capitaux propres | -158.0% |
Quelles ont été les performances à long terme de CLVS.Q?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2023/07/12 18:46 |
| Cours de l'action en fin de journée | 2023/07/10 00:00 |
| Les revenus | 2022/09/30 |
| Revenus annuels | 2021/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Clovis Oncology, Inc. est couverte par 16 analystes. de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Debjit Chattopadhyay | Brean Capital Historical (Janney Montgomery) |
| Douglas Buchanan | Brean Capital Historical (Janney Montgomery) |